This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hypersensitivity angiitis과민성 혈관염

Contents and key points
ItemDetails
A. Classification codesICD-10: M31.0 | Special Copayment Reduction: V290 (severe intractable disease, 5 years)
B. SynonymsHypersensitivity small-vessel vasculitis; Leukocytoclastic vasculitis; Cutaneous small-vessel vasculitis
C. Adult onsetAdult onset: High — Hypersensitivity angiitis can occur at any age but occurs mainly in adults. It occurs from various causes such as drugs, infection, and autoimmune disease.
1. HistorySee main text
2. CausesSee main text
3. GeneticsSee main text
4. General epidemiologySee main text
5. PathophysiologySee main text
6. SymptomsSee main text
7. SignsSee main text
8. ScreeningSee main text
9. DiagnosisSee main text
10. TreatmentSee main text
11. PrognosisSee main text
12. PreventionSee main text
13. ReferencesSee main text

1. History

Hypersensitivity angiitis is a vascular inflammatory reaction involving small vessels (arterioles, capillaries, venules), and began to be recognized clinically in 1952 when Davson and Zollinger described necrotizing vasculitis of small skin vessels. The term 'hypersensitivity angiitis' has been used mainly to refer to small-vessel vasculitis caused by hypersensitivity reactions to drugs or infection. In the 1990 ACR classification criteria, hypersensitivity angiitis was included as an independent classification. In the 2012 revised International Chapel Hill Consensus Conference nomenclature system, the name was revised to 'cutaneous small-vessel vasculitis (CSV),' but in ICD-10 it is retained as M31.0 (hypersensitivity angiitis).

In the history of treatment, discontinuing the causative drug and steroids were the main treatments, and in the 1990s the efficacy of colchicine in treating cutaneous vasculitis was demonstrated in a randomized controlled trial. Cyclophosphamide has been used in severe vasculitis with visceral involvement, and with the introduction of rituximab for the treatment of ANCA-associated vasculitis, treatment options for severe vasculitis have expanded.


2. Causes

The causes of hypersensitivity angiitis are varied. Drugs are the most common cause and include antibiotics (penicillin, cephalosporin, sulfonamides), NSAIDs, diuretics, anticonvulsants, propylthiouracil, TNF inhibitors, and other biologic agents. Infection: hepatitis B and C viruses, HIV, streptococcal infection, and Helicobacter pylori are associated. Autoimmune disease: may accompany SLE, RA, Sjögren syndrome, and inflammatory bowel disease. Malignancy: occurs as a paraneoplastic syndrome in hematologic cancers (lymphoma, myelodysplasia) and solid cancers. Unknown cause (idiopathic) accounts for about 40-50%. Deposition of immune complexes (IgG, IgM, IgA, complement) in the small vessel wall and complement activation are the common mechanism.


3. Genetics

Specific genetic susceptibility to hypersensitivity angiitis has not yet been sufficiently elucidated. In IgA vasculitis (Henoch-Schönlein purpura, HSP/IgAV), HLA-B35, HLA-DRB1*01, and HLA-DQA1*0103 are associated with susceptibility. C4A deletion and complement gene variants may reduce immune complex clearance and contribute to the development of vasculitis. In drug-induced hypersensitivity angiitis, polymorphisms in drug-metabolizing enzyme genes (N-acetyltransferase, CYP2C9, etc.) determine individual differences in immune response to drugs.


4. General epidemiology

The exact prevalence of hypersensitivity angiitis is unknown, and the annual incidence is estimated at about 30-60 per million. It occurs at all ages but is more common in adults. In drug-induced cases, it appears within 7-21 days after use of a specific drug. IgA vasculitis (Henoch-Schönlein purpura) is more common in children and tends to be more severe in adults. The prognosis differs greatly by cause, and most drug-induced cases improve spontaneously within weeks after the causative drug is discontinued.


5. Pathophysiology

Immune complexes are deposited in the small vessel wall and activate complement (classical pathway), and C3a/C5a activate mast cells and basophils to increase vascular permeability. Increased ICAM-1 expression on vascular endothelial cells draws neutrophils into the vessel wall, and degranulation of activated neutrophils (elastase, MPO, etc.) and ROS production cause vessel wall damage. Deposition of neutrophil nuclear debris (nuclear dust) around vessels is the characteristic histopathologic finding of leukocytoclastic vasculitis (LCV). In some cases, a T-cell-mediated delayed-type hypersensitivity reaction (type IV) is also involved.


6. Symptoms

Palpable purpura is the most characteristic skin symptom and occurs predominantly on the lower extremities (especially below the ankles, areas of gravity-dependent blood stasis). The purpura does not fade with pressure (non-blanchable). Urticarial vasculitis, blisters, and skin ulcers may also appear. Arthralgia (non-deforming polyarticular), fever, malaise, and myalgia may accompany. With visceral involvement: abdominal pain (mesenteric vessel involvement), hematuria/proteinuria (kidney involvement), arthritis, lung involvement (cough, dyspnea). In IgA vasculitis, abdominal pain and hematuria are more common.


7. Signs

Palpable purpura centered on the lower extremities is the characteristic finding. Ankle edema and joint tenderness may accompany. With visceral involvement, abdominal tenderness, elevated blood pressure (kidney involvement), and abnormal lung auscultation appear. Blood tests: CBC (anemia, leukocytosis), elevated CRP/ESR, decreased complement (C3, C4) (when immune complexes are activated), elevated serum IgA (IgA vasculitis), ANCA positivity (perform ANA, anti-dsDNA, RF, ANCA tests). Urinalysis: hematuria, proteinuria. Skin biopsy (findings of leukocytoclastic vasculitis, checking for IgA deposition on immunofluorescence).


8. Screening

There is no screening test for the general population. If a rash or purpura develops within 7-21 days after use of a new drug, suspect the causative drug immediately. In patients with chronic autoimmune disease (SLE, RA, Sjögren syndrome), actively evaluate for vasculitis when skin purpura occurs. Include serologic tests to exclude infectious causes (hepatitis B and C, HIV). Assess kidney involvement (hematuria, proteinuria) and other visceral involvement to determine whether systemic vasculitis is present.


9. Diagnosis

Skin biopsy (4 mm punch biopsy of a purpuric area with a negative blanching test) is the diagnostic standard. Histopathology: neutrophil infiltration around small vessels (venules, capillaries), nuclear debris (leukocytoclasis), fibrin deposition in the vessel wall, and extravasation of red blood cells are characteristic of LCV. Immunofluorescence (direct immunofluorescence, DIF): if IgA deposition is confirmed, it supports a diagnosis of IgA vasculitis (Henoch-Schönlein purpura). Evaluation of cause: drug history, infection (hepatitis B and C viruses, streptococcal ASO), autoantibodies (ANA, ANCA, RF, cryoglobulin), complement, urinalysis, chest X-ray. Differentiate ANCA-associated vasculitis (GPA, MPA, EGPA), cryoglobulinemic vasculitis, PAN, SLE vasculitis, thrombocytopenic purpura, and pigmented purpuric dermatosis.


10. Treatment

Removal of the cause: Discontinuing the causative drug is the most important first step. Most drug-induced hypersensitivity angiitis improves spontaneously within weeks after drug discontinuation. Mild to moderate cutaneous vasculitis: colchicine (0.6 mg twice daily), dapsone (50-150 mg/day), antihistamines. Leg elevation and compression stockings help. Moderate to severe or recurrent: systemic steroids (prednisolone 0.5-1 mg/kg/day). Visceral involvement or severe systemic vasculitis: high-dose steroids + immunosuppressant (azathioprine, MMF) or cyclophosphamide. Kidney involvement in IgA vasculitis: steroids ± cyclophosphamide. When identified as ANCA-associated vasculitis, treat according to the relevant guidelines. Rituximab is effective in certain types of severe vasculitis.


11. Prognosis

Drug-induced hypersensitivity angiitis has an excellent prognosis after discontinuation of the causative drug. Most cases improve spontaneously within weeks. It may worsen on recurrence or repeated exposure. The prognosis worsens when there is visceral (kidney, bowel, lung) involvement, and in particular the degree of kidney involvement determines the long-term prognosis. The adult form of IgA vasculitis has more common and more severe kidney involvement than in children. Cases classified as ANCA-associated vasculitis require more aggressive immunosuppressive treatment.


12. Prevention

Recognizing the causative drug and discontinuing it promptly is the most important preventive measure. Avoid re-exposure to drugs that previously caused hypersensitivity angiitis. Hepatitis B vaccination prevents infectious causes. Active management of autoimmune diseases such as RA and SLE reduces the risk of autoimmune vasculitis. Smoking cessation helps maintain vascular health.


13. References

  1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512-1523.
  2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
  3. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-317.
  4. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48(3):311-340.
  5. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107.
  6. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222-227.
  7. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine. 2005;84(5):313-322.
  8. Sunderkötter C, Sindrilaru A. Clinical classification of vasculitis. Eur J Dermatol. 2006;16(2):114-124.
  9. Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 2010;56(1):3-23.
  10. Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol. 1995;131(12):1399-1402.